

## Supplementary Online Content

Huh S-Y, Kim S-H, Hyun J-W, Joung A-R, Park MS, Kim B-J, Kim HJ. Mycophenolate Mofetil in the Treatment of Neuromyelitis Optica Spectrum Disorder. Published online September 8, 2014. *JAMA Neurology*. doi: 10.1001/jamaneurol.2014.2057

**eTable.** Summarization of the outcome of previous treatments, MMF, and rituximab treatment

This supplementary material has been provided by the authors to give readers additional information about their work.

**eTable.** Summarization of the outcome of previous treatments, MMF, and rituximab treatment

Patients	Brief IS history	ARR before MMF (duration, mo)	ARR on MMF (duration, mo)	ARR on RTX (duration, mo)	Note
1	AZA→MMF→RTX	2.00 (43)	1.63 (22)	1.09 (21)	
2	MITOX→MMF→RTX	3.61 (76)	0.60 (20)	0.21 (56)	
3	MMF→RTX	1.11 (22)	2.20 (16)	0.00 (30)	Relapse free after RTX
4	MMF→RTX	1.58 (53)	1.50 (16)	1.0 (24)	2 relapses during first 2 months of RTX, no relapse for the next 22 months of RTX
5	AZA→MITOX→MMF→RTX	2.04 (70)	0.80 (15)	0.00 (63)	Relapse free after RTX
6	MMF→RTX	1.06 (23)	2.23 (5)	0.63 (19)	
7	MITOX→MMF→RTX	2.10 (46)	2.39 (5)	3.43 (7)	*2 relapses during 7 months of RTX
8	AZA→MMF→RTX	1.49 (32)	2.61 (5)	0.00 (18)	Relapse free after RTX
9	AZA→MMF→RTX	4.58 (10)	2.63 (5)	0.63 (19)	
10	AZA→MMF→RTX	0.92 (40)	1.87 (7)	0.25 (48)	

AZA: azathioprine; MMF: mycophenolatemofetil; RTX: rituximab; MITOX: mitoxantrone; ARR: annual relapse rate; IS: immunosuppressants.

\*This patient did not follow the RTX treatment protocol due to financial reason